The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Ex vivo drug sensitivity profiling to guide treatment selection in R/R multiple myeloma
Raffaella Cassano, MD, University of Pisa, Pisa, Italy, discusses a prospective trial (NCT03389347) evaluating ex vivo drug sensitivity profiling to guide treatment selection in patients with high-risk relapsed/refractory (R/R) multiple myeloma. She highlights how testing myeloma cells against different drugs may help identify effective treatments for patients who have received at least three prior lines of therapy or experienced early relapse after autologous stem cell transplantation. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this scenario, when we can administer a lot of drugs, we need to select a specific drug that can work on each patient. So the idea of this study that we already performed and want to do in the future is that we can select patient cells, so plasma cells affected by myeloma, and control on them the response to different kinds of drugs. And then it could be useful to predict in clinical life, so in the real world, which kind of treatment could be effective for each patient...
In this scenario, when we can administer a lot of drugs, we need to select a specific drug that can work on each patient. So the idea of this study that we already performed and want to do in the future is that we can select patient cells, so plasma cells affected by myeloma, and control on them the response to different kinds of drugs. And then it could be useful to predict in clinical life, so in the real world, which kind of treatment could be effective for each patient. We enroll patients after three lines of treatment, so refractory after three lines of treatment before, or patients who are very early relapsed, so patients that relapse after 12 months after transplant. So, very, in our opinion, these are very high-profile patients because they have some kind of features that can be analyzed for high-risk myeloma, high-risk functional myeloma. I think that the key point of this kind of study, so the drug sensitivity study, it could be that the DSS, this core drug sensitivity, could be useful to guide the treatment selection so when we analyze the endpoints also the threshold that we can do like a real endpoint for the drug sensitivity score we can use it to select the specific drug for patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
